EINSTEIN-Jr. is a clinical development program seeking data to support the use of rivaroxaban in children with VTE. Results from the COLUMBA study were presented at the 2019 ASH Annual Meeting. Frailty can adversely affect the outcomes of allogeneic hematopoietic cell transplantation (alloHCT). A global study observed an increased trend in autologous hematopoietic cell transplantation among patients with MM. The results were presented at the 2019 ASH Annual Meeting. Peter M. Voorhees, MD, discussed B-cell maturation antigen (BCMA)-targeted CAR T-cell treatment strategies. The Pleiades study assessed subcutaneous (SC) versus intravenous (IV) administration of daratumumab. CD123 expression is strongly correlated with disease-relevant cytogenetic and molecular alterations in AML. The analysis identified 505,230 admissions in 2014. Patients report poor adherence to the 2015 Dietary Guidelines for Americans and are not receiving necessary daily nutrients. In this patient population, high-dose cytarabine consolidation is usually given in the inpatient setting. Prior reports have indicated that minorities with cancer have worse outcomes than white patients. Amrita Krishnan, MD, discussed treatment options for patients with relapsed multiple myeloma. The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone improved response in patients with MM. The ongoing GO29781 study assessed mosunetuzumab in patients with relapsed/refractory B-cell NHL. Nina Shah, MD, discussed the latest updates in multiple myeloma therapies and regimens. Daratumumab is approved for IV administration as monotherapy or with standard of care regimens for MM. Acalabrutinib alone or in combination with obinutuzumab improved survival in patients with treatment-naïve CLL. Many patients report that they are not counseled about their concerns. Older patients and those who are racially and socioeconomically disadvantaged are more frequently undergoing AHCT.